Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling

被引:122
作者
Kistemaker, Loes E. M. [1 ,2 ]
Gosens, Reinoud [1 ,2 ]
机构
[1] Univ Groningen, Dept Mol Pharmacol, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands
关键词
anticholinergics; M-3; receptor; muscarinic receptor subtypes; mechanical strain; non-neuronal acetylcholine; AIRWAY SMOOTH-MUSCLE; OBSTRUCTIVE PULMONARY-DISEASE; NONNEURONAL CHOLINERGIC SYSTEM; RECEPTORS MEDIATE STIMULATION; BRONCHIAL EPITHELIAL-CELLS; MUSCARINIC M3 RECEPTOR; HUMAN LUNG FIBROBLAST; TIOTROPIUM BROMIDE; MYOFIBROBLAST TRANSITION; DEPENDENT MECHANISM;
D O I
10.1016/j.tips.2014.11.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acetylcholine is the primary parasympathetic neurotrans. mitter in the airways, where it not only induces bronchoconstriction and mucus secretion, but also regulates airway inflammation and remodeling. In this review, we propose that these effects are all primarily mediated via the muscarinic M-3 receptor. Acetylcholine promotes inflammation and remodeling via direct effects on airway cells, and via mechanical stress applied to the airways sequential to bronchoconstriction. The effects on inflammation and remodeling are regulated by both neuronal and non-neuronal acetylcholine. Taken together, we believe that the combined effects of anticholinergic therapy on M-3-mediated bronchoconstriction, mucus secretion, inflammation, and remodeling may account for the positive outcome of treatment with these drugs for patients with chronic pulmonary obstructive disease (COPD) or asthma.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 86 条
[1]   Thromboxane A2 induces airway constriction through an M3 muscarinic acetylcholine receptor-dependent mechanism [J].
Allen, IC ;
Hartney, JM ;
Coffman, TM ;
Penn, RB ;
Wess, J ;
Koller, BH .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2006, 290 (03) :L526-L533
[2]  
[Anonymous], GINA REP GLOB STRAT
[3]   EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[4]   One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium [J].
Anzueto, A ;
Tashkin, D ;
Menjoge, S ;
Kesten, S .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2005, 18 (02) :75-81
[5]  
Asano Kazuhito, 2010, Int J Chron Obstruct Pulmon Dis, V5, P277
[6]   The role of anticholinergics in chronic obstructive pulmonary disease [J].
Barnes, PJ .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 :24S-32S
[7]  
Barnes PJ, 2000, CHEST, V117, P63
[8]   Alternative mechanisms for tiotropium [J].
Bateman, E. D. ;
Rennard, S. ;
Barnes, P. J. ;
Dicpinigaitis, P. V. ;
Gosens, R. ;
Gross, N. J. ;
Nadel, J. A. ;
Pfeifer, M. ;
Racke, K. ;
Rabe, K. F. ;
Rubin, B. K. ;
Welte, T. ;
Wessler, I. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2009, 22 (06) :533-542
[9]   Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma [J].
Beeh, Kai-Michael ;
Moroni-Zentgraf, Petra ;
Ablinger, Othmar ;
Hollaenderova, Zuzana ;
Unseld, Anna ;
Engel, Michael ;
Korn, Stephanie .
RESPIRATORY RESEARCH, 2014, 15
[10]   Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Wedzicha, JA .
THORAX, 2000, 55 (02) :114-120